Linzess denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for linzess are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a Not-FDA-Approved Denial for Linzess

This denial type is uncommon for Linzess because it is an FDA-approved drug — however, Aetna may issue a "not-FDA-approved" or "off-label" denial when Linzess is prescribed for a condition or patient population outside its current approved labeling. FDA approval is indication-specific, so even an approved drug can be denied if prescribed for a diagnosis that falls outside the approved indications listed in the prescribing label. Confirm the exact indication listed on the prescription and compare it to the FDA label.

## Why This Denial Is Appealable

Off-label use of FDA-approved drugs is a recognized and common medical practice, and many state insurance laws and federal guidelines require coverage when off-label use is supported by established medical compendia or peer-reviewed evidence. Even if a strict "not-approved" standard applies, ACA §2719 external review rights and ERISA §503 full-and-fair review rights apply. File an internal appeal within the deadline shown on the denial notice; request external review within approximately four months of exhausting internal remedies. Expedited review is available if your health would be jeopardized by delay.

## The Concrete Appeal Process

1. Confirm the submitted diagnosis code: verify the ICD-10 code on the prescription and claims submission matches the approved indication in the FDA label. 2. If the indication is on-label, provide Aetna with the FDA-approved prescribing label showing the indication and request the denial be reconsidered. 3. If the use is off-label, document support from recognized compendia (such as those listed in your state's insurance statutes) and relevant gastroenterology guidelines by organization name. 4. File a formal internal appeal and request external IRO review if internal appeal fails.

## Documentation to Gather

• FDA-approved prescribing label: attach the current full prescribing information for Linzess showing approved indications.
• Prescribing diagnosis code: a letter from the prescriber confirming the diagnosis and the specific indication for which Linzess was prescribed.
• Medical-necessity letter: the prescriber explains how the patient's condition fits the approved indication, referencing the chart record.
• Applicable guideline citations: reference the guideline organization (e.g., the American College of Gastroenterology) without inventing statistics; let the published guideline document speak for itself.
• State law reference: if your state has a law requiring coverage of off-label use supported by compendia, cite it in your appeal.

## Criteria-Mapping Structure

Map each element of Aetna's denial reason to the specific counter-evidence. If the denial says the indication is not approved, attach the FDA label page showing it is. If the denial says off-label use is not covered, cite the applicable state law or plan term that permits coverage with compendia support. A direct, document-anchored response is far more effective than a narrative appeal alone.